Member Info for inanaco

how can Johnney come lately win if he does not buy before the RNS ? Your just posting nonsense, many are in with higher averages, but then they are in for that one RNS ... your another party that claims success after knowing the result ... .... are you holding today ? are you a buyer today or a seller ? if your going to claim the high ground at least prove your future trading history by declaring a position today

How do you get the message across and for it to sink in ......... no one media "hits Target" all you can do is wait for that one RNS that draws in every ones attention ... just like OXB just did however Johnny come's lately never wins to the same degree

Its very difficult to argue the science is wrong as its transparent, research papers patents trial data etc etc etc which has quantifiable commercial value but how do you argue the SP is Right ? if you cannot prove its worth less ... but only prove its worth more only one outcome ...buy and hold.

well its been a interesting 6 years, and that history of looking into every aspect of scancell has allowed me to absorb and understand an incredible amount of science. which is why i can post with such confidence, and that really upsets folks that just don't respect that understanding has taken years, its not something you pick up in 5 mins .. the problem thou is it does create issues if your a party that needs to "stand out" .... like ONW who is desperate to appear as a party that can provide an alternative, problem then is how to you overcome the logic of scancells science which is completely at odds with the SP.

I am a buyer .... market has completed missed what scancell has achieved, and has been doing it since the trend down started. leaving folks with "why is it so cheap" must be something wrong ... LOL tick tock

did not respond to that RNS and actually went down, i could not believe it, so i started buying for the simple reason you only get that sort of RNS with efficacy ... never looked back ... Tick Tock

19 June 2012 Scancell Holdings Plc ('Scancell' or the 'Company') SCIB1 Trial Update - Approval to dose patients for up to 5 years Scancell Holdings Plc, (AIMSCLP), the developer of therapeutic cancer vaccines, is pleased to announce that the Gene Therapy Advisory Committee ('GTAC') and the Medicines and Healthcare Products Regulatory Agency ('MHRA') Medicines Division have given their approval to increase the maximum treatment period from 6 months up to a further 5 years in its Phase I/II clinical trial of SCIB1, its DNA ImmunoBody� vaccine being developed for the treatment of melanoma. The continuation option will be available for patients with stable disease. Approval was also granted to further broaden the study inclusion criteria. In addition, Scancell's partner Ichor Medical Systems ('Ichor') has obtained the required parallel approval from the MHRA Devices Division for the use of Ichor's TriGrid� electroporation delivery device to administer SCIB1 for this extended period. The clinical trial of SCIB1 is being conducted at five leading UK hospital centres in Nottingham, Manchester, Newcastle, Leeds and Southampton. Prof. Lindy Durrant, Joint CEO of Scancell, commented: "This approval from GTAC and MHRA provides our Investigators with the opportunity to continue dosing patients whose disease has not progressed whilst receiving the SCIB1 vaccine and will allow the Company to gather longer term data on late stage melanoma patients for whom the prognosis is poor." A copy of this announcement is available for download on the Company's website at http://www.scancell.co.uk/

u did made a 39% gain thou ... but held through the spike. what killed the SP was not investors but that RNS Notice of Results and Share Price Movement Mon, 8th Oct 2012 10:31 RNS Number : 1521O Scancell Holdings Plc 08 October 2012 Notice of Results and Share Price Movement Scancell Holdings plc ("Scancell"or the "Company") Scancell (AIM: SCLP), the developer of therapeutic cancer vaccines, is pleased to announce that its results for the year ended 30 April 2012 will be released on 12 October 2012. The board of Directors of the Company also notes the rise in the Company's share price. The Directors are not aware of any reason that would lead to such a movement in its price. even thou for some reason you blamed me !

I dont wish to create yet more conflict C7 .. but are you sure you purchased Scancell before Moditope news Broke ? 15 August 2012

we already have 7 patients past the 5 year "golden marker" and patients are now being cured by immunotherapy from Car T and the check point inhibitors. The question now is "% of cured"

problem is my post trump his with quality content ...

and So does everybody else ONW . or had you not noticed everyone agrees with me on the science. The predictions i laid down on the science over many years have all come good. Now the commercial aspects ...... i laid down "Arm Holdings" .......... do you think that scancell appears on the surface to be following this course ? I appreciate that a "to good to miss offer" could still catch us out, but that would have to be in the Billions rather than millions as I fear that Scancell can easily convince holders at an EGM to stay with the BOD

ONW clearly you have not posted with sufficient reasoning to be able to understand what your posting. a clearly defined "alternative view" is not in evidence .... all i have done is posted the "factual content" of the history of scancell over laid to the SP i am sure if you can post with similar precision then an "alternative view" could be formed. until then all you can do is attack me with waffle ...

what alternative view ?? if you post un-reasoned v reasoned ... you only get one outcome what proof have you that scancell behaved like a Rabbit in headlights .. ? when the science just developed consistently while the SP trended down ... Or have i missed something.

You write a lot ... but actually say little

To a depth that you can instantly translate that science into the general market of "standard of Care" in oncology, and how the competing immunotherapy has developed and is developing, you can see that Scancell actually does not have competition, what it does have is Synergy .. The low SP has allowed us of the years to transfer into ISA and indeed increase under that umbrella so i would say this, since my first buys at 8p in 2012, with an expected exit at �3 with capital gains tax to pay .... has transformed into Wait the dividends .... they will be many many multiples of the Current SP yearly and retain the capital base for the life of the patents in that tax free shelter .. Its the perfect pension ... small in, huge return out

all deals on the table ONW ... that is what investors want to hear ... but so far the evidence is individual deals and partnerships indicating the preferred route to market is "arm Holdings" I Got a lot of stick for suggesting it .......... back then. funny how stuff i post years ago finally comes the norm.

Design the wheel round in the first place. The market still has not understood that, indeed it moans about cash raising at low levels , but forgets that the market has driven the SP low in the first place due to lack of understanding in that scenario Scancell has been fighting an up hill battle even thou it has the backing of CRUK, BioNtech, ISA pharma, and Roche, and support from the Top Oncologists in melanoma the market still has not re-rated the share yet. add in the new Glycan platform ... which i have not even mentioned makes this saga fascinating ... which is why i keep buying

Lindy has worked hard to achieve this TH1 slew you can research this yourself, The very nature of moditope action requires "inflammation" to induce Epitope expression resulting in the flipping of the tumour environment resulting in Clonal expansion of T cells over powering the cancers ability to cloak Immunobody did not need this slew ... that's how good it is it induces the correct T cell from the vaccine but is stopped in its tracks by the PD1 ligand on Solid tumours which is why its good for adjuvant melanoma but struggles with late stage. hence the Combo with PD1 poor vaccines need a boost Functions IL-12 is involved in the differentiation of naive T cells into Th1 cells.[2] It is known as a T cell-stimulating factor, which can stimulate the growth and function of T cells. novio�s INO-5401, an immunotherapy encoding multiple cancer antigens, is designed to generate and activate T-cells to many cancer types including bladder cancer. INO-9012, an immune activator encoding IL-12, is designed to amplify and accelerate T cell immune responses to INO-5401. basically they need to "improve the T cells " .. Scancell induces high avidity Inovio does not ...

I just posted that chap .. Big pharma are again looking at Vaccines and Scancell wants the trial data first , or be offered a deal it cannot refuse Scancell is in a position of strength, Big Pharma is not, they keep having failed combo trials, and cannot seem to get an innate response good enough to support the PD1 efficacy